Pharmacyclics-Janssen's ibrutinib wins third breakthrough status

04/9/2013 | Fox Business · RTT News

The FDA granted a third breakthrough therapy designation to Pharmacyclics and Janssen Biotech's experimental oral agent ibrutinib as a treatment for chronic lymphocytic leukemia or small lymphocytic lymphoma with deletion of the short arm of chromosome 17. The designation was based on positive data from preclinical and clinical trials.

View Full Article in:

Fox Business · RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ